A Federal Circuit panel seemed to resist Genentech Inc.’s efforts Wednesday to pull a generic Amgen Inc. cancer treatment off the shelves for six months.

Genentech told a Federal Circuit panel that Amgen failed to serve the 180-day notice of commercial marketing required by the Biologics Price Competition and Innovation Act when, in August 2018, it supplemented its Food and Drug Administration application for Mvasi, Amgen’s biosimilar version of Genentech’s $3 billion-a-year drug Avastin.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]